Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392574 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT00392574 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 282 participants.
The verdict
NCT00392574, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.
Interventions
- DRUG Placebo
- DRUG Prulifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392574
The ClinicalTrials.gov registry entry for NCT00392574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00392574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392574 about?
NCT00392574 is a clinical study titled "Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea". The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.
What is the current status of trial NCT00392574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2006-08. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00392574?
The interventions under investigation include: Placebo (DRUG), Prulifloxacin (DRUG).
Who is sponsoring clinical trial NCT00392574?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.